VSIR and non-small cell lung carcinoma: VISTA expression correlated with improved overall survival in pT1/2 esophageal adenocarcinoma [160], HCC [141], and ovarian cancer [161]; 5-year survival for NSCLC [162]; and disease-free survival for estrogen-receptor-negative, progesterone-receptor-negative, and invasive ductal carcinoma [163].